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Abstract 
 
Introduction: Anterior-oblique (AO) proton beams form an attractive option for 
prostate patients receiving external beam radiotherapy (EBRT) as they avoid the 
femoral heads. For a cohort with hydrogel prostate-rectum spacers, we asked 
whether it was possible to generate AO proton plans robust to end-of-range 
elevations in linear energy transfer (LET) and modelled relative biological 
effectiveness (RBE). Additionally we considered how rectal spacers influenced 
planned dose distributions for AO and standard bi-lateral (SB) proton beams 
versus intensity-modulated radiotherapy (IMRT).  
 
Material and methods: We studied three treatment strategies for ten patients with 
rectal spacers: (A) AO proton beams, (B) SB proton beams and (C) IMRT. For 
strategy (A) dose and LET distributions were simulated (using the TOPAS 
Monte Carlo platform) and the McNamara model was used to calculate proton 
RBE as a function of LET, dose per fraction, and photon α/β. All calculations 
were performed on pre-treatment scans: inter- and intra- fractional changes in 
anatomy/set-up were not considered. 
 
Results: For 9/10 patients, rectal spacers enabled generation of AO proton plans 
robust to modelled RBE elevations: rectal dose constraints were fulfilled even 
when the variable RBE model was applied with a conservative α/β=2Gy. 
Amongst a subset of patients the proton rectal doses for the PTV plans were 
remarkably low: for 2/10 SB plans and 4/10 AO plans, ≤10% of the rectum 
received ≥20 Gy. AO proton plans delivered integral doses a factor of ~3 lower 
than IMRT and spared the femoral heads almost entirely.  
 
Conclusion: Typically, rectal spacers enabled the generation of anterior beam 
proton plans that appeared robust to modelled variation in RBE. However, 
further analysis of day-to-day robustness would be required prior to a clinical 
implementation of AO proton beams. Such beams offer almost complete femoral 
head sparing, but their broader value relative to IMRT and SB protons remains 
unclear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Anterior-oblique (AO) proton beams form an attractive option for prostate 
patients receiving external beam radiotherapy (EBRT) as they avoid the femoral 
heads / hip prostheses. It has previously been suggested that, assuming a fixed 
Relative Biological Effectiveness (RBE) of 1.1, range-verified AO proton beams 
could reduce the mean dose to the rectum, anterior rectal wall and penile bulb by 
a factor of ~2 relative to standard bilateral (SB) proton beam arrangements (1). 
Using restricted weightings such beams have already been applied clinically in 
conjunction with lateral portals by a consortium of three centres which published 
a report on the treatment of twenty patients (2). However, if a complete EBRT 
dose prescription was to be split between two AO proton beams, the distal edges 
of these beams would necessarily coincide with the boundary between the 
prostate and the rectum. This prompts two concerns regarding rectal dose: (i) 
variations in patient anatomy, particularly bladder and rectal filling, might result 
in proton range-overshoot and (ii) increased RBE at the distal edge of each AO 
field might result in unacceptable hotspots in rectal “biological dose”. An 
emerging trend in prostate therapy that could mitigate both of these concerns is 
the use of synthetic poly(ethylene glycol) hydrogel, introduced into the 
retroprostatic space. 	  
Injected hydrogel spacers (SpaceOAR, Augmenix Inc.) typically result in a 
separation of ~1cm between the rectum and prostate (3). This separation remains 
stable over 10-12 weeks (4) enabling substantial rectal dose reductions in the 60-
70 Gy region (5). A multicentre, randomized controlled trial was conducted in 
222 men with stage T1 or T2 prostate cancer treated using image-guided IMRT 
to 79.2 Gy with or without rectal spacers. The spacer group experienced a 
significant reduction in late rectal toxicity severity (p=0.044) as well as lower 
rates of decrease in bowel quality of life at 6, 12 and 15 months compared to the 
control group (6). Further, the spacer technique has been reported as cost 
effective (7). 
 
For a cohort of patients without rectal spacers, we recently demonstrated that AO 
proton beam plans that appeared dosimetrically suitable assuming a fixed RBE 
of 1.1 no longer fulfilled rectal dose constraints when variable RBE weighted 
(vRBEw) dose models were applied (8). In this work we studied the impact of 
rectal spacers upon AO proton beam plans. We asked whether it was possible to 
generate AO proton plans robust to end-of-range elevations in linear energy 
transfer (LET) and modelled RBE, the distal beam edge of the proton beam 
being positioned within the hydrogel rather than the anterior rectal wall. Given 
the trend towards prostate hypofractionation, we assessed the impact of large 
doses per fraction on RBE elevation at the distal edge of a proton SOBP. 
Additionally we considered how rectal spacers influenced planned dose 
distributions for anterior-oblique and lateral proton beams versus IMRT. 
 
Material and Methods 
 
Ten patients with low/intermediate risk prostate cancer were studied, all treated 
sequentially using a commercial rectum-prostate spacer system (SpaceOAR; 
Augmenix, Waltham, MA). SpaceOAR hydrogel plus fiducials were implanted, 
and planning CTs plus axial T2-weighted MR images with a limited field of 
view were acquired 3-5 days later. The MR images were rigidly registered to the 
planning CT using MIM (MIM Software Inc). The clinical target volume (CTV) 
was defined as the prostate alone. Endo-rectal balloons were not applied. 
 
Three treatment planning techniques were considered:  
(A) Anterior-oblique (AO) proton beams. Beam angles of ±35° beam 
angles were selected to avoid the femoral heads, avoid beam overlap on 
skin surface and reduce bladder dose relative to smaller angular 
separations. 
(B) SB proton beams (±90°).  
(C) 7 field IMRT. With beam angles of 0°, 60°, 100°, 135°, 225°, 260°, 
300°. 
 
Both (A) and (B) were implemented as spot-scanned single field uniform dose 
(SFUD) proton plans using multi-criteria optimisation (MCO) within Astroid, 
our in-house treatment planning system (TPS). The in-air sigma of the proton 
spot varied from 12mm at 60MeV to 4.6mm at 230MeV at isocenter. The IMRT 
plans (C) were implemented using MCO in the Raystation TPS (Raysearch 
Laboratories, Sweden).  
 
For each planning technique, (A)-(C), two different strategies for planning target 
volume (PTV) margins were applied: (i) a 5mm CTV to PTV expansion, uniform 
in all directions; (ii) no PTV expansion, i.e. using the CTV as the sole target. For 
a summary of our complete planning methodology, please see supplementary 
table 1. Whilst margin-free planning (strategy (ii)) is clearly not advisable in 
current clinical practice, we consider it here the extreme of what might be 
achievable with gating, increased image guidance / adaptation and, in the case of 
proton therapy, in-vivo range verification. 
 
For all planning modalities our strategy was to minimize the rectal dose, subject 
to fulfillment of our clinical requirements (Table 1). Our MCO objectives and 
constraints are detailed in Supplementary Table 2. Where inter-modality 
comparisons of dosimetric statistics were performed, we used the (non-
parametric) Wilcoxon signed-rank test for related samples. 
 
Table 1: clinical dose requirements (rigidly enforced for all plans) 
Clinical Target Volume (CTV) At least 90% volume at 79.2 Gy  
At least 99% volume at 77.6 Gy 
Planning Target Volume (PTV) 
(strategy (i): only applied for a 
subset of plans) 
At least 95% volume at 77.6 Gy  
Bladder At most 80 Gy at 10% volume 
At most 75 Gy at 15% volume 
At most 70 Gy at 25% volume 
At most 65 Gy at 30% volume 
At most 55 Gy at 45% volume 
At most 45 Gy at 50% volume 
Rectum At most 1cm3 at 83.16 Gy 
At most 75 Gy at 10% volume 
At most 70 Gy at 15% volume 
At most 60 Gy at 30% volume 
At most 50 Gy at 45% volume 
At most 40 Gy at 50% volume 
Femoral heads At most 45 Gy at 5% volume 
 
 
For the AO proton plans dose and dose-averaged LET distributions were 
calculated using TOPAS (TOol for PArticle Simulations, version 2.0.3) (9). It 
has been demonstrated that, relative to Monte Carlo (MC) simulations, proton 
pencil beam algorithms typically over-estimate the mean dose delivered to deep-
seated targets such as the prostate by approximately 2% whilst under-estimating 
the scattered dose to normal tissues (15). Consequently, in this study proton 
plan-specific scaling factors were applied to the MC dose-distributions so that 
the dose received by 90% of a patient’s CTV volume matched that for their 
IMRT plan.  
 
Voxel-by-voxel, the McNamara model (10) was used to calculate RBE for the 
AO proton plans as a function of dose per fraction, dose-averaged LET and 
photon α/β. As proposed by the QUANTEC organ-specific papers, we typically 
considered a photon α/β of 3 Gy for the rectum (11) and bladder (12), but also 
tested a range of 2-6 Gy. Evidence suggests that the prostate has a lower photon 
α/β of approximately 1.5 Gy: here we considered a range of 0.5 to 4 Gy (13) (14) 
(15). Our standard fractionation scheme was 44 x 1.8 Gy (16), but to additional 
regimens drawn from photon practice were also considered in the variable RBE 
modeling: 20 x 3 Gy (17) and 5 x 7.25 Gy (18). Where relevant, equivalent 
uniform dose (EUD) values were calculated assuming a-values of 5, 7 and -10 
for the rectum, bladder and prostate respectively (19). Integral energy 
depositions were calculated for the whole body minus the target volume, 
assuming a body composition of water. 
 
Results 
 
Assuming a fixed proton RBE of 1.1 
For a fixed RBE of 1.1 the plans produced according to strategies (A)-(C) (table 
1) were well-matched in terms of target coverage, all fulfilling the clinical dose 
requirements detailed in table 1. Figure 1 and supplementary table 3 compare 
dosimetric data across strategies (A)-(C) for the rectum and bladder. For our 
implementation of IMRT it was not possible to further spare the rectum at the 
expense of increased bladder dose. Additional rectal sparing for IMRT could 
only be achieved by forfeiting clinical requirements, particularly those for target 
coverage. Similarly, for both proton beam configurations the best achievable 
rectum and bladder DVHs were largely limited by the target coverage 
requirements, rather than trade-offs between rectum and bladder dose. 
 
 
 
(a) Plans with uniform 5mm CTV to PTV expansion 
 
(b) Plans with no CTV to PTV expansion 
Figure 1: DVH comparison between treatment planning strategies (A)-(C) (see 
table 1) for all 10 rectum spacer patients. Each solid / dashed line corresponds to 
a DVH plot for an individual patient; the shaded regions indicate the inter-patient 
range for each plan type. 
 
First we considered plans with a uniform 5 mm CTV to PTV margin (see Figure 
1a and supplementary table 3a). AO and SB plans both outperformed IMRT in 
terms of rectal dose statistics, in a manner that was statistically significant for 
dose levels up to 60 Gy (p<0.05). For the rectum, the calculated mean rectum 
equivalent uniform dose (EUD) values for the AO, SB and IMRT plans were 
approximately 27 GyRBE, 29 GyRBE and 38 Gy respectively. Figure 1a 
demonstrates the inter-patient variation in spacer efficacy. Amongst a subset of 
patients the proton rectal DVH plots were remarkably low: for 2/10 SB plans and 
4/10 AO plans ≤10% of the rectum received ≥20 Gy. For the bladder, the 
calculated mean EUD values for the AO, SB and IMRT plans were 
approximately 54 GyRBE, 53 GyRBE and 54 GyRBE respectively. Although the 
bladder EUD values were relatively well-matched, significant differences in 
mean bladder dose and bladder fractional volume receiving 30 Gy were evident 
between the three techniques. In terms of greatest bladder sparing the techniques 
ranked: (1) SB protons (2) IMRT (3) AO protons. 
 
Similar trends are evident in Figure 1b where no CTV to PTV expansion was 
applied within any of the techniques. Relative to IMRT, the proton plans 
maintain a rectal dose advantage at levels ≤30 Gy, but at a slight cost to bladder 
dose. Further data on these plans is included in supplementary table 3ab. 
 
Overall, regardless of margin choice, if a fixed proton RBE of 1.1 can be 
assumed then, relative to SB proton beams and IMRT, AO proton beams may 
deliver improved rectal and femoral head dosimetry at the expense of additional 
bladder dose. The integral energy deposited was also substantially lower for AO 
protons than for SB protons and IMRT: calculated mean values were 37.5 J, 49.9 
J and 114.0 J respectively, for the 5mm PTV plans (supplementary table 3a). 
 
Modelling RBE variation for the AO proton beams 
For AO proton beams, figure 2 exemplifies how the highest vRBEw dose values 
arise the distal edge of the PTV target (see the color-wash gradient in vRBEw 
dose). Nonetheless, for nine out of ten cases the rectal spacer provided a barrier 
sufficient for the rectal maximum dose constraint to be fulfilled for the PTV 
plans (figure 3a), even when the McNamara variable RBE model was applied 
with photon α/β values of 2 to 6 Gy. In the left panels (a and b), the case where 
the rectal spacer was least effective is shown: here, at the inferior levels, no gap 
is created by the spacer between the prostate and the rectum. The panels on the 
right (c and d) show a more typical case, where superiorly to inferiorly the spacer 
forms a buffer for the full length of the prostate PTV. The reader will note that in 
figure 2, application of the McNamara model with an α/β of 3 Gy resulted in 
modelled biological doses in the target far exceeding the prescription level (79.2 
GyRBE). This finding is further reflected in figure 3b, where the modelled EUD 
within the CTV is plotted as a function of prostate α/β. The variable RBE model 
suggests that assuming a fixed RBE of 1.1 leads us substantially underestimate 
the biological dose delivered. 
 
For the standard fractionation scheme considered in this study (44 x 1.8 Gy) the 
model predicted RBE values exceeding 1.3 at the distal edge of a standard SOBP 
(for α/β values of 1.5 Gy and 3 Gy), as shown in figure 3c. However, for a 
hypofractionated regimen with a dose per fraction of 7 Gy (20) and the same α/β 
values, the maximum modelled RBE value at the distal edge was <1.2. 
Consequently, the model predicted that a dose per fraction of 7 Gy could limit 
biological dose elevation at the beam distal edge to 10%, compared to 20% for 
the standard fractionation scheme. However, if high values of the ratio: (vRBEw  dose)!/!!!.!  !"  (vRBEw  dose)!/!!!  !"    
are taken to indicate therapeutic advantage, i.e. increased cell kill in the tumor 
compared to the normal tissue, then the 44 x 1.8 Gy regimen appeared preferable 
(figure 3d). This suggests that if we were to optimize IMPT plans according to 
the variable RBE model (applying a variable RBE constraint to rectal dose) then 
standard fractionation would enable the highest biological-dose boosts to the 
target.  
 
Supplementary table 4a demonstrates that, when the McNamara model was 
applied with an α/β of 3 Gy, the rectal dose performance of plans both with and 
without a uniform 5mm CTV to PTV expansion was similar to that of IMRT (no 
significant difference was found in modelled EUD).  
 
 
  
(a) Sagittal view of case where spacer was 
least effective 
(c) Sagittal view of more typical case 
  
(b) Axial view of case where spacer was 
least effective 
(d) Axial view of more typical case 
Figure 2: demonstrations of vRBEw dose distributions for AO spot-scanned proton therapy 
plans with a uniform 5mm CTV to PTV margin (strategy A(i) in Table 1). The PTV target 
is contoured in black; the hydrogel, contoured using additional MR data, is shown in blue; 
and the rectum is contoured in pink. The dose distributions overlaid here are for vRBEw 
dose calculated according to the McNamara model with an α/β of 3 Gy. 
 
  
(a) Plans with uniform 5mm CTV to 
PTV expansion: boxplots of the 
maximum dose to 1cc of the rectum for 
all 10 patients. The horizontal line 
shows the constraint that no 1cc of the 
rectum should receive more than 103% 
of the prescription dose. 
(b) Plans with uniform 5mm CTV to 
PTV expansion: boxplots of the CTV 
equivalent uniform dose (EUD) for all 
10 patients, assuming an EUD a-value 
of -10 (19). 
  
(c) Example application of the 
McNamara model for various 
fractionation schemes and α/β values 
(d) Considering the ratio (vRBEw dose 
with an α/β of 1.5 Gy)/(vRBEw dose 
with an α/β of 3 Gy) for the 
for a simple proton SOBP in water, 
range = 20 cm, modulation = 10 cm 
fractionation schemes show in figure 
3(c) 
Figure 3: Investigating the McNamara model’s (10) sensitivity to α/β value and 
fractionation regimen 
 
 
Discussion 
 
Assuming a fixed RBE of 1.1, we found that AO protons enabled a greater 
degree of rectal sparing than SB protons or IMRT. For plans with no CTV to 
PTV expansion, statistically significant differences between IMRT and AO 
protons persisted in dose regions up to 30 Gy, whereas for the plans with a 
uniform CTV to PTV expansion of 5mm, the improvement persisted to a dose 
level of 60 Gy. Our findings are consistent with a previous study, where of 
VMAT, IMRT and bilateral IMPT, after spacer injection only IMPT managed to 
decrease the rectal dose at a broad range of dose levels (5).  
We demonstrated previously that, for a cohort without rectal spacers, AO proton 
beams were not robust to modelled elevations in proton RBE: use of such beams 
could result in unacceptably high rectal doses (8). Here we show that for cases 
with rectal spacers, it is typically (9 times out of 10) possible to generate AO 
proton plans with a uniform 5mm CTV to PTV margin expansion that are robust 
to variable RBE modelling. That is, when implanted successfully, rectal spacers 
suitably mitigate the RBE uncertainties associated with AO proton beams. 
However, imperfect hydrogel insertion could prove problematic in an AO proton 
beam protocol: in the one case where it was not possible for us to generate a 
“biologically robust” AO proton plan with a 5 mm PTV, no gap was created 
between the rectum and the prostate at inferior levels. Clinicians would need to 
remain mindful that asymmetric / non-homogeneous insertions could lead to 
hotspots in rectal biological dose. 
 
We did not consider spacer stability, and thus efficacy, over the course of an 
EBRT treatment. However, clinical data suggest that initial hydrogel volumes are 
well-preserved over 10-12 weeks (4). A recent photon dosimetric study 
demonstrated that for CT scans acquired 1 day, 1 month and 2 months post 
hydrogel injection, adaptive radiotherapy would lead to only minor 
improvements in rectal DVH compared to use of a single plan (21). In this work 
equal CTV to PTV margins of 5mm were applied for all proton and IMRT plans. 
Additional analyses would be required to determine whether equal margins 
would correspond to matched levels of clinical robustness, for example in terms 
of inter-fractional changes in anatomy and set-up errors (22,23), intra-fractional 
motion (24) and proton-specific issues such as water-equivalent path length 
variation (25). In the long-term, in-vivo proton range verification and plan 
adaptation could also facilitate the application of AO beams, for example using 
diodes attached to a rectal balloon (26).   
It should be noted that whilst a number of clinical studies have reported hydrogel 
spacers to be safe (3,6), one published case report linked a rectal ulcer to a 
hydrogel insertion (27) and their use was halted in a recent trial, where two rectal 
fistulas were presumed due to the gradual accumulation of gel within the 
confines of the anterior rectal wall, as seen on magnetic resonance imaging 
during the course of the treatment (28). However, the latter publication reported 
that in addition to gel migration, variations in individual patient radiosensitivity 
could have played a role, on-treatment image guidance was limited to orthogonal 
X-rays (it did not state whether alignment based on bony anatomy or prostate 
fiducials), and the in-vivo dose to the anterior rectal wall was not known 
precisely (25). The quality of the initial gel placement was not described and 
ultimately the exact source of the fistulas remains unknown.  
AO proton beams have generated clinical interest, mainly due to their capacity to 
spare the femoral heads almost entirely in a manner useful for patients with hip 
replacements or with previously irradiated hips (2). Assuming a fixed RBE of 
1.1, AO proton beams are also associated with integral doses ~3 times lower than 
IMRT and offer rectal sparing in the low to medium dose region (<30 Gy) 
relative to both SB proton beams and IMRT. However, the benefits of AO proton 
beams come at a cost to increased bladder dose at all levels. As yet there is no 
consensus as to whether rectal or bladder sparing should be the first priority in 
prostate radiotherapy. Data from one recent study suggests that bladder sparing 
should be prioritized: patients with consistent quality of life (QOL) reduction in 
urinary irritation function were significantly associated with greater mean 
bladder dose, whereas none of the evaluated rectal dosimetric parameters showed 
a significant correlation with QOL score change in bowel function (29). 
However, the study was retrospective and limited to 1 year of follow-up for 86 
patients treated using stereotactic body radiation therapy. Other work suggests 
that complete rectal DVHs are important in determining patient reported 
outcome (30). Thus for a cohort with hydrogel spacers, it isn’t clear whether the 
additional rectal sparing offered by AO protons (relative to IMRT or SB protons) 
is likely to prove clinically meaningful or not. 
 
Questions over the clinical desirability of AO proton beams are further 
complicated by uncertainties in proton RBE. The transition from a fixed RBE 
value of 1.1 to a variable RBE model resulted in increased target EUD in 
addition to increased rectal biological dose. Thus if variable RBE models could 
be validated in vivo, new possibilities to dose-boost the prostate and/or improve 
normal tissue sparing would arise. Whilst hypofractionation could further limit 
potential RBE elevations at the distal edge of AO proton beams, ultimately – if 
vRBEw dose models were used in plan optimization - standard fractionation 
should provide the greatest advantage in terms of target relative to normal tissue 
dose.  
 
In conclusion, typically rectal spacers enabled the generation of anterior beam 
proton plans that appeared “biologically robust”, that is robust to modelled 
elevations in variable RBE. While our results do depend on the accuracy of the 
dose calculation method, the beam characteristics (e.g. the steepness of the distal 
fall-off), the accuracy of the RBE model, our parameters can be considered 
representative. However, we performed all calculations on treatment planning 
CT scans we did not consider inter- and intra- fractional changes in anatomy/set-
up: analysis of day-to-day robustness would be required prior to a clinical 
implementation of AO proton beams, particularly with regards to bladder and 
rectum filling and thus proton under-/over-shoot. For patients where sparing of 
the femoral heads is a priority, AO proton beams form an appealing solution. But 
given uncertainties in both (i) proton RBE and (ii) the relative importance of 
bladder versus rectum dose-sparing, the broader value of AO proton beams - 
relative to SB protons and IMRT - remains unclear. 
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